$19.6M defending a mark, not buying a discountRamin Kamfar · Bluerock Private Real Estate Fund · NYSE: BPRE
- What was done
- Bluerock Asset Management LLC — an entity Ramin Kamfar controls — bought BPRE shares on the open market on sixteen trading days across four weeks. Every Form 4 reports the ownership as indirect, “purchased through an entity controlled by the Reporting Person,” with no 10b5-1 plan.
| Tranche | Shares | Wtd avg | Approx value | Holdings after |
|---|---|---|---|---|
| 28–30 Sep | 425,590 | $12.50–$12.61 | $5.35M | 906,360 |
| 6–9 Oct | 651,063 | $12.99–$13.17 | $8.50M | 1,827,031 |
| 15–21 Oct | 465,783 | ~$12.45 | $5.80M | — |
| Total | 1,542,436 | — | ~$19.65M | — |
| BPRE 23 Oct close | — | $12.45 | NAV $22.47 | −44.95% |
Consensus read
The sponsor is buying a dollar of real estate for fifty-five cents. A 45% discount to NAV on a portfolio of private real estate funds, with the manager stepping in with $19.6M of its own capital, is emphatic alignment and evidence the discount is a liquidity artefact of the recent listing rather than a valuation judgement.
Steelmanned: discounts on newly listed vehicles genuinely do overshoot when previously locked-up holders finally get an exit, and buying that supply is exactly what a manager who believes its own book should do.
Contrarian read
The discount is the market’s verdict on the NAV, and the buyer is the party with the strongest commercial incentive to dispute that verdict, because its management fee is charged on net assets it calculates itself. The $22.47 is a mark on private holdings. The $12.45 is the only arms-length price these assets have.
These purchases are not a bet that the shares are cheap. They are a defence of the mark — and buying is cheaper than remarking the book.
Evidence that discriminates
- The discount did not move. Across four weeks and 1.54 million shares, the price went $12.50 (28 Sep) → $13.17 (9 Oct) → $12.45 (23 Oct). The campaign ended below where it started. If this were value buying into an irrational discount, tightening the float by that much should narrow it. It did not. A conviction buyer who is right gets paid; a buyer absorbing structural supply does not.
- The buyer is the fee-earning entity, not the man. Every filing reports indirect ownership through Bluerock Asset Management LLC. Kamfar’s personal account appears in none of them. A principal who believes a dollar is on sale for fifty-five cents buys it himself; he does not route it through the company whose revenue is a percentage of the number being defended. This is the single field that separates the two readings and it is the field every headline drops.
- The fund is bidding too, and says why. BPRE announced a repurchase programme on 16 December 2025, explicitly for buying shares back “when they trade below net asset value.” Two balance sheets on the same bid is a price-support operation. Two independent investors reaching the same conclusion do not coordinate their timing to the day.
- The cadence. Sixteen trading days in four weeks, essentially continuous. Conviction accumulation is episodic and price-seeking; within the 6–9 Oct tranche he bought the most shares on the cheapest day and the second-most on the dearest. There is no price sensitivity in the pattern. (Inference from the Form 4 line items.)
What would falsify me
A Form 4 showing Kamfar buying BPRE directly, with personal funds. That removes the central field observation and makes this an ordinary insider conviction trade.
An arms-length secondary print on BPRE’s underlying private fund holdings anywhere near the stated NAV. If the mark is defensible against a real transaction, the discount is a liquidity artefact and the consensus read wins.
The discount narrowing materially over the next quarter without further adviser buying. That would show the supply was transient and I have mistaken absorption for support.
PatternAgainst his own history this is unprecedented in cadence: sixteen buying days in four weeks, through a controlled entity, with no trading plan. The −44.95% discount is from a single source (CEF Connect, 23 Oct); the $12.45 market price independently matches the implied average of the 15–21 Oct Form 4 tranche, which is a useful cross-check on the price but not on the NAV.